Dr. Lal PathLabs Declares Q4/FY26 Results, ₹4 Dividend, Acquires SDCPL

Dr. Lal PathLabs Ltd. announced its Board of Directors' decisions from the meeting on April 30, 2026. The Board approved the Audited Standalone & Consolidated Financial Results for the Quarter and Financial Year ended March 31, 2026. A final dividend of INR 4/- per equity share (40% on face value of INR 10/-) was recommended for FY26, with June 26, 2026, as the record date. The company also approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a Wholly Owned Subsidiary. Furthermore, the incorporation of a new Wholly Owned Subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE, was approved. The Board re-appointed Dr. Arvind Lal as Executive Chairman and Whole-Time Director and Mr. Rajit Mehta as a Non-Executive Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. M/s Ernst & Young LLP and M/s A.G. Agarwal & Associates were re-appointed as Internal and Cost Auditors, respectively. Lastly, 82,750 Equity Shares were allotted under the Employee Stock Option Plan 2022.